H2 regulates HO-1 and HMGB1 in sepsisScientific Research


original title: Hydrogen plays a protective role in intestinal injury of mice with severe sepsis by regulating the release of heme oxygenase-1 and high mobility group protein B1

Authors:

Ling Yin, Man Yang, Yang Yu, Keliang Xie, Yonghao Yu

DOI: 10.3760/cma.j.cn121430-20200717-00533

-

Abstract:

Objective: To investigate the protective effect of the hydrogen (H2) inhalation on intestinal injury in severe sepsis mice and its relationship with nuclear factor E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1)/high mobility group protein B1 (HMGB1) pathway.

Methods: The 280 male wild-type (WT) and Nrf2 knockout (Nrf2-KO) ICR mice (6-8 weeks old, 20-25 g weight) were assigned into 8 groups randomly (WT and Nrf2-KO mice, 4 groups respectively, n = 35): Sham group, H2 inhalation group (Sham+H2 group), sepsis model group which was induced by cecal ligation and puncture (CLP group) and H2 treatment group (CLP+H2 group). In Sham group, except cecal ligation and perforation, the same surgery was used. The mice in Sham group and CLP group inhaled only air for 1 hour and 6 hours, respectively, while the mice in Sham+H2 group and CLP+H2 group inhaled 2% H2 for 60 minutes. After modeling, 20 mice randomly in each group were selected to measure 7-day natural survival rates; the remaining mice(15 mice) were killed in 24 hours after modeling, and the bacterial load was determined by collecting the peritoneal lavage fluid (PLF) of each mouse to measure the colony forming unit (CFU); and the intestinal tissue was taken after perfusion, and the intestinal tissue of 3 mice was used to extract protein for HO-1 and HMGB1 levels by using Western blotting. Intestinal tissue of 3 mice was extracted to prepare histomorphology sections for the identification of HO-1. Intestinal tissue of 3 mice was used to detect the expression of HMGB1 by immunofluorescence.

Results: The 7-day survival rate of WT and Nrf2-KO mice in CLP group was zero; in WT mice, the 7-day survival rate of CLP+H2 group was significantly higher than that of CLP group (45% vs. 0%, P < 0.05), while no difference of the 7-day survival rate in Nrf2-KO mice was noted between CLP and CLP+H2 groups (0% vs. 0%, P > 0.05). Compared with Sham group, the CFU in the PLF of both mice in CLP group increased significantly. Compared with CLP group, 2% H2 treatment could significantly improve the bacterial clearance rate of WT mice with severe sepsis (CFU, ×103: 34.7±6.3 vs. 74.2±8.1, P < 0.01), but had no significant effect on Nrf2-KO mice with severe sepsis (CFU, ×103: 73.3±7.5 vs. 75.8±8.6, P > 0.05). The results of Western blotting, immunohistochemical and immune-fluorescence showed that the expression of HO-1 and HMGB1 in the CLP group were higher than those in the Sham group. Compared with CLP group, the expression of HO-1 in WT mice of CLP+H2 group was significantly higher [HO-1 protein expression (HO-1/β-actin): 0.716±0.035 vs. 0.460±0.045, HO-1 positive expression (A value): 0.703±0.135 vs. 0.430±0.116, both P < 0.01], while the expression of HMGB1 was significantly lower [HMGB1 protein expression (HMGB1/β-actin): 0.052±0.038 vs. 0.082±0.008, HMGB1 positive expression (A value): 24.530±9.317 vs. 41.830±2.458, both P < 0.01]. In Nrf2-KO mice, compared with CLP group, there was no statistical difference in the above indexes in CLP+H2 group [HO-1 protein expression (HO-1/β-actin): 0.148±0.004 vs. 0.164±0.043, HO-1 positive expression (A value): 0.109±0.020 vs. 0.113±0.025, HMGB1 protein expression (HMGB1/β-actin): 0.109±0.020 vs. 0.113±0.025, HMGB1 positive expression (A value): 39.570±12.660 vs. 42.790±9.680, all P > 0.05]. Conclusions: H2 can inhibit the intestinal injury of mice with severe sepsis through Nrf2/HO-1/HMGB1 pathway, and Nrf2 plays an important role in the treatment of intestinal injury with H2.

Hydrogen Therapy At Home

Beyond clinical settings, hydrogen therapy is successfully used at home — thanks to our internationally recognised devices.

At “Hydrogen Technologies” Ltd., for more than 15 years we have been developing and manufacturing “HHO Bulgaria” devices for health with hydrogen.

We are among the pioneers in the field and, unlike many of our competitors worldwide, we continue to exist and to innovate!

By choosing “HHO Bulgaria”, you support both your own health and Bulgarian innovation and manufacturing.

Meet HBS10 — Europe’s best-selling hydrogen therapy device, both in Bulgaria and worldwide.

HBS10 — Hydrogen therapy device

HBS10 → More about HBS10 TOP PRODUCT

Inhalation and water

H2 therapy device
2-in-1

Output

Hydrogen inhalation
450 ml
HHO gas per minute

Concentration

Hydrogen water
-250 mV
ORP

The device is a 2-in-1 system: use it for hydrogen inhalation or to prepare hydrogen-rich water (“hydrogen water”).

HBS10 is the only European hydrogen therapy device chromatographically tested for safety at the Bulgarian Academy of Sciences (BAS)!

In addition, the device is:

  • CE certified;
  • Tested and recommended by the renowned hydrogen therapy platform H2HUBB, USA.

Order online

H2BOOSTR Mini is our newest alternative for hydrogen therapy at home.

H2BOOSTR Mini — hydrogen water system with 100% pure molecular hydrogen

H2BOOSTR Mini → More about H2BOOSTR NEW

100% pure molecular hydrogen

100%
pure molecular
hydrogen

Ready in 30 seconds

30 seconds
to prepare

High hydrogen concentration

3.2–3.6 mg
hydrogen
per litre of water

The system saturates water with 100% pure molecular hydrogen (“hydrogen water” with maximum dissolved hydrogen).

H2BOOSTR Mini reflects Bulgarian innovation: the technology is fully engineered in Bulgaria and is the world’s only solution that prepares one litre of hydrogen water in just 30 seconds with over 3 ppm of 100% pure molecular hydrogen!

Order online

FREE PERSONAL
CONSULTATION

  • SHORT AND
    STRAIGHT TO THE POINT
  • SPECIFIC
    TO YOUR NEEDS
  • CLEAR, AND IN
    EASY-TO-UNDERSTAND LANGUAGE

Discover How Molecular Hydrogen Therapy
can help You
and Your Loved Ones.

Ask The World's First Specialized H2 Consultant,
equipped with knowledge acquired from:

2500+

Clinical Studies,
Scientific Reports and Publications
conducted Worldwide

Analyses, consultations and summaries, prepared and published on our websites by Medical Specialists:

  • Dr. Ivan Vlasov
  • Dr. Victoria Kaludova
Sylvia Panayotova - H2 Consultant

Trained by:

Sylvia
Panayotova

Hydrogen Therapy Consultant,
certified by the Molecular Hydrogen
Institute (MHI) in the U.S.